Literature DB >> 24317371

Development of an open metadata schema for prospective clinical research (openPCR) in China.

W Xu1, Z Guan, J Sun, Z Wang, Y Geng.   

Abstract

OBJECTIVES: In China, deployment of electronic data capture (EDC) and clinical data management system (CDMS) for clinical research (CR) is in its very early stage, and about 90% of clinical studies collected and submitted clinical data manually. This work aims to build an open metadata schema for Prospective Clinical Research (openPCR) in China based on openEHR archetypes, in order to help Chinese researchers easily create specific data entry templates for registration, study design and clinical data collection.
METHODS: Singapore Framework for Dublin Core Application Profiles (DCAP) is used to develop openPCR and four steps such as defining the core functional requirements and deducing the core metadata items, developing archetype models, defining metadata terms and creating archetype records, and finally developing implementation syntax are followed.
RESULTS: The core functional requirements are divided into three categories: requirements for research registration, requirements for trial design, and requirements for case report form (CRF). 74 metadata items are identified and their Chinese authority names are created. The minimum metadata set of openPCR includes 3 documents, 6 sections, 26 top level data groups, 32 lower data groups and 74 data elements. The top level container in openPCR is composed of public document, internal document and clinical document archetypes. A hierarchical structure of openPCR is established according to Data Structure of Electronic Health Record Architecture and Data Standard of China (Chinese EHR Standard). Metadata attributes are grouped into six parts: identification, definition, representation, relation, usage guides, and administration. DISCUSSIONS AND
CONCLUSION: OpenPCR is an open metadata schema based on research registration standards, standards of the Clinical Data Interchange Standards Consortium (CDISC) and Chinese healthcare related standards, and is to be publicly available throughout China. It considers future integration of EHR and CR by adopting data structure and data terms in Chinese EHR Standard. Archetypes in openPCR are modularity models and can be separated, recombined, and reused. The authors recommend that the method to develop openPCR can be referenced by other countries when designing metadata schema of clinical research. In the next steps, openPCR should be used in a number of CR projects to test its applicability and to continuously improve its coverage. Besides, metadata schema for research protocol can be developed to structurize and standardize protocol, and syntactical interoperability of openPCR with other related standards can be considered.

Entities:  

Keywords:  Dublin Core Metadata Element Set (DC Metadata Element Set); Metadata; archetype; clinical research (CR); electronic health record (EHR)

Mesh:

Year:  2013        PMID: 24317371     DOI: 10.3414/ME13-01-0008

Source DB:  PubMed          Journal:  Methods Inf Med        ISSN: 0026-1270            Impact factor:   2.176


  3 in total

1.  Information Technology for Clinical, Translational and Comparative Effectiveness Research. Findings from the Yearbook 2015 Section on Clinical Research Informatics.

Authors:  C Daniel; R Choquet
Journal:  Yearb Med Inform       Date:  2015-08-13

2.  Construction of a Meta-Evidence Prototype Database of Traditional Chinese Medicine Splenogastric Diseases and Its Application in an Automatic Meta-Analysis System.

Authors:  Xueqin Zhang; Chunying Wang; Yanning Yao; Wenyu Sun; Yujie Guo; Lin Ma; Xinyuan Lu; Hongyong Deng
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-13       Impact factor: 2.650

3.  Accessing and sharing health information for post-discharge stroke care through a national health information exchange platform - a case study.

Authors:  Nadia Davoody; Sabine Koch; Ingvar Krakau; Maria Hägglund
Journal:  BMC Med Inform Decis Mak       Date:  2019-05-03       Impact factor: 2.796

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.